Trial Profile

Trial to Reduce Cardiovascular Events with Aranesp Therapy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darbepoetin alfa (Primary)
Indications Anaemia
Focus Adverse reactions; Registrational
Acronyms TREAT
Sponsors Amgen

Most Recent Events

01 Oct 2015 Pooled analysis of 2 studies of total 4854 patients including patients from this TREAT trial and other RED-HF trial [see CTP 700244591] were published in the European Journal of Heart Failure.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com